Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 311

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 311
---
Certain Relationships

There are no family relationships between or among
the Board or executive officers. 

Annual Meeting Attendance

Our policy is to invite and encourage each member
of our Board to be present at any annual meetings of stockholders. During the year ended December 31, 2024, there was no annual meeting
of stockholders.

Director Compensation

We did not pay any compensation, make any equity awards
or non-equity awards to or pay any other compensation to any of our non-employee directors during the year ended December 31, 2024. In
addition, we reimburse all directors for travel and other necessary business expenses incurred in the performance of their services for
us.

Board Leadership Structure

In accordance with our Amended and Restated Bylaws
(“Bylaws”), our Chief Executive Officer serves as the Chairman of the Board. The Board determined that in the best interest
of the Company, the most effective leadership structure at this time is not to separate the roles of Chairman and Chief Executive Officer
pursuant to the Bylaws. A combined structure will provide the Company with a single leader who represents the Company to our stockholders,
regulators, business partners and other stakeholders. In addition, this structure will create efficiency in the preparation of the meeting
agendas and related Board materials as the Company’s Chief Executive Officer works directly with those individuals preparing the
necessary Board materials and is more connected to the overall daily operations of the Company. Agendas will also be prepared with the
permitted input of the full Board allowing for any concerns or risks of any individual director to be discussed as deemed appropriate.
The Board believes that the Company will benefit from this structure, and Mr. King’s continuation in the combined role of the Chairman
and President and Chief Executive Officer is in the best interest of the stockholders.

 41 

In addition, the Board does not currently have a lead
independent director. The Board has determined that this structure is the most effective leadership structure for our Company at this
time based on its size. In addition, our Audit, Compensation and Corporate Governance and Nominating Committees, which oversee critical
matters such as our accounting principles, financial reporting practices and system of disclosure controls and internal controls over
financial reporting, our executive compensation program and the selection and evaluation of our directors and director nominees, each
consist entirely of independent directors.

Board Risk Oversight

The Board does not have a standing risk management
committee, but rather administers this oversight function directly